Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S175000, C514S470000
Reexamination Certificate
active
06878745
ABSTRACT:
Drugs for preventing and/or treating progressive lesions after organ damage without inhibiting the function of the organ or the regeneration function thereof, by selectively regulating the induction of cytotoxic effecter macrophages which are induced into damaged organ tissues in response to chemokines or cytokines expressed depending on the type of the damaged organ tissues.
REFERENCES:
patent: 45-20956 (1970-07-01), None
patent: 04-338331 (1992-11-01), None
J.L. Derrick Clive et al., “Synthesis of the Angiotensin-Converting Enzyme Inhibitors (-)-A58365A and (-)-A583658 from a Common Intermediate”, J. Org. Chem., vol. 64, No. 5, pp. 1447-1454, 1999, chemical compound 9.
M. Ishibashi et al., Cellular Immune Response Against Human Red Blood Cell Antigens and Renal Allograft Rejection. Transplant Proc, 1987, 19:4511-4515.
M. Ishibashi et al., Immunologic Studies of Red Cell Antigens in the Renal Transplant Patient. Transplant Proc, 1984, 16:1509-1511.
M. Ishibashi et al., Monocyte-mediated Hemolytic Response in Renal Transplant Patients. Transplant Proc, 1985, 17: 2644-2647.
M. Ishibashi et al., Novel Effector Moncytes Against Human RBC Antigens Invading Rejected Renal Allografts. Transplant Proc, 1988, 20: 285-288.
M. Ishibashi et al., Immunologic Effects of Immunosuppressive Agents Explored by a New Effector Monocyte Genertion Assay. Transplant Proc, 1989, 21: 1854-1858.
M. Ishibashi et al., A Gamma-lactone Immunosuppressant Inhibits the Generation of Macrophage Killer Cells and Prolonged skin Allograft Survival in the Rat. Transplant Proc, 1992, 24: 1411-1412.
A. Moutabarrik et al., Monocyte Hemolytic Activity as an Immunologic Indicator of Allograft Rejection in Rat Skin Transplantation. Transplant Proc, 1992, 24: 403-407.
M. Ishibashi et al., Nonspecific Hemolytic Effector of Activated Macrophages as Activation Marker of Allograft Rejection. Transplant Int, 1992, 5 (Suppl. 1): S290-S295.
M. Ishibashi et al., Prevention of Chronic Rejection of Renal Allografts in Rat Using a Synthetic Inhibitor of Macrophage Effector Activation. Transplant Proc, 1995, 27: 564-565.
H. Azuma et al., Prevention of Functional, Structural and Molecular Changes of Chronic Rejection of Rat Renal Allografts by a Specific Macrophage Inhibitor. Transplantation, 1995, 60: 1577-1582.
M. Ishibashi et al., Prevention of Chronic rejection and Puromycin-induced Giomerulosclerosis in Rats by Gamma-Lactone, as an Inhibitor of Macrophage-effector Activation. Transplant Proc, 1996, 28: 953-954.
M. Ishibashi et al., Attenuation of Glomerular Epithelial Cell Innury and Diminution of Tubulointerstitial Lesions by a Macrophage Inhibitor in Chronic Puromycin-nephrosis model. Nephrology, 1997; 3 (Suppl. 1): S44.
M. Ishibashi et al., Combined use of Selective Inhibitor of Macrophage-effector Generation for Treatment of Differential Glomerular and Tubulointerstitial Lesion of Progressive Renal Diseases. Abstract submitted to the 35th Amer. Soc. of Nephrology, Pennsylvania, Oct. 30-Nov. 4, 2002.
Ishibashi Michio
Mioskowski Charles
Sylvain Catherine
Wagner Alain
Ishibashi Michio
Weddington Kevin E.
Wenderoth, Lind & Ponack, L.L.C.
LandOfFree
Selective preventives/remedies for progressive lesions after... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective preventives/remedies for progressive lesions after..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective preventives/remedies for progressive lesions after... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3373824